Cost-utility analysis of transcranial direct current stimulation (tDCS) in non-treatment-resistant depression: the DISCO randomised controlled study protocol

Anne Sauvaget 1,2, Lydie Lagalice, 1 Solène Schirr-Bonnans, 3 Christelle Volteau, 4 Morgane Péré, 4 Cécile Dert, 3 Annabelle Rivalland, 1 Fabienne Tessier, 1 Adeline Lepage, 1 Agathe Tostivint, 1 Thibault Deschamps, 2 Véronique Thomas-Ollivier, 2 Alison Robin, 2 Noémie Pineau, 2 Clémence Cabelguen, 1 Nicolas Bukowski, 1 Marie Guitteny, 1 Auxane Beslot, 1 Luc Simons, 1 HUGOPSY Network, 5 Jean-Marie Vanelle, 1 Giordano D’Urso, 6 Samuel Bulteau, 1,7 Valéry-Pierre Riche, 3 DISCO investigators group

ABSTRACT

Introduction Depression is among the most widespread psychiatric disorders in France. Psychiatric disorders are associated with considerable social costs, amounting to €22.6 billion for treatment and psychotropic medication in 2011. Treatment as usual (TAU), mainly consisting of pharmacotherapy and psychotherapy, is effective for only a third of patients and in most cases fails to prevent treatment resistance and chronicity. Transcranial direct current stimulation (tDCS) consists in a non-invasive and painless application of low-intensity electric current to the cerebral cortex through the scalp. Having proved effective in depressed patients, it could be used in combination with TAU to great advantage. The objective is to compare, for the first time ever, the cost-utility of tDCS-TAU and of TAU alone for the treatment of a depressive episode that has been refractory to one or two drug treatments.

Methods and analysis This paper, based on the DISCO study protocol, focuses on the design of a prospective, randomised, controlled, open-label multicentre economic study to be conducted in France. It will include 214 patients with unipolar or bipolar depression, assigning them to two parallel arms: group A (tDCS-TAU) and group B (TAU alone). The primary outcome is the incremental cost-effectiveness ratio, that is, the ratio of the difference in cost between each strategy to the difference in their effects. Their effects will be expressed as numbers of quality-adjusted life-years, determined through administration of the EuroQol Five-Dimension questionnaire over a 12-month period to patients (EQ-5D-5L). Expected benefits are the reduction of treatment resistance and suicidal ideation as well as social and professional costs of depression. Should depression-related costs fall significantly, tDCS might be considered an efficient treatment for depression.

Ethics and dissemination This protocol has been approved by a French ethics committee, the CPP—Est IV (Comité de Protection des Personnes—Strasbourg). Data are to be published in peer-reviewed medical journals.

Strengths and limitations of this study

► The DISCO study protocol is the first economic evaluation comprising a comparative cost-utility analysis of transcranial direct current stimulation (tDCS) plus treatment as usual (TAU) versus TAU alone, for the treatment of depression.
► The study will yield new information to improve primary care of patients with non-resistant unipolar or bipolar depression.
► It has one of the longest follow-ups in brain stimulation research.
► The DISCO study is flexibly designed, calling for administration of tDCS at a frequency varying with the needs of individual patients—as opposed to applying a rigid timepoint protocol—which better reflects actual clinical practice and is of greater benefit to both patients and study centres.
► As a real-life study, the study does not involve changes in current patient treatments.

Trial registration number RCB 2018-A00474-51; NCT03758105

INTRODUCTION

Background and rationale

Major depressive disorder (MDD) is one of the most widespread psychiatric disorders worldwide. It has an estimated prevalence of 5%–12% in the French population 1 2 and a substantial impact on patients’ health and quality of life. A systematic analysis of the Global Burden Study in 2010 revealed that unipolar depression represents the second greatest cause of the increase of
years lived with disability and that its prevalence had not declined over the preceding 20 years despite therapeutic advances. Psychiatric disorders also have a considerable socioeconomic cost: in 2011, treatments and consumption of psychotropic drugs in France accounted for €22.6 billion, or 16% of total health expenditures there. Despite appropriate treatments, 30%–40% of patients suffering from MDD show no improvement. Only a third of patients achieve clinical remission after one antidepressant drug treatment step, while up to four treatment steps are necessary to reach clinical remission for approximately 70% of patients. Moreover, an increased risk of relapse is reported for those who require more than one drug treatment to achieve remission. Treatment resistance is defined as the failure to achieve remission after at least two different antidepressant administration phases at an effective dosage over a period of 6 weeks. In these cases, higher dosages may be necessary, as well as combination and augmentation strategies.

Transcranial direct current stimulation (tDCS) is a treatment technique consisting in the non-invasive and painless application of low-intensity electric current to the cerebral cortex through the scalp. No longer confined to the research setting, tDCS is now being used in everyday clinical practice and at new facilities entirely dedicated to psychiatric neuromodulation. It is a non-pharmacological psychiatric therapy that has proven effective in patients with MDD as well as those with other psychiatric and neurological conditions, including obsessive-compulsive disorder, schizophrenia, post-traumatic stress disorder, addiction, autism spectrum disorder, and dementia.

According to Canadian Network for Mood and Anxiety Treatments MDD management guidelines, tDCS’s sister technique, repetitive transcranial magnetic stimulation (rTMS), has already reached the highest level of evidence of efficacy (level 1) in patients not responding after administration of one antidepressant. Compared with rTMS, tDCS is less studied but has the advantage of being easier to perform and less expensive.

It has been demonstrated that patients with depressive disorder present hypofunction and cerebral abnormalities of the dorsolateral prefrontal cortex, which can be reversed by means of anodal (excitatory) tDCS. Most meta-analyses show that active tDCS is significantly more effective than sham tDCS in terms of MDD patient response and remission rates. Although tDCS has also proved effective in treatment-resistant depression, the level of resistance is predictive of the degree of tDCS efficacy. It would thus appear that tDCS is ideally for use in patients with depressive disorder with a low level of resistance to pharmacological treatment. To date, most studies evaluating tDCS treatment have focused on unipolar depression. Nevertheless, a recent meta-analysis including 13 studies showed a significant decrease of depression after tDCS treatment in bipolar depression. Interestingly, certain depressive symptoms were associated with a better response to tDCS treatment. Moreover, although tDCS represents a promising alternative treatment for depression but its popularity was lower than other neurostimulation therapies, its long-term efficacy has yet to be fully demonstrated. A study highlighted that 45% of patients were still in remission 3 months after 10 sessions of tDCS and that the relapse rate seemed to increase with the interval between tDCS sessions. Recent recommendations call for more studies with maintenance tDCS and long-term evaluation of the effect of tDCS in patients with depressive disorder.

Objectives and trial design
The main purpose of this randomised controlled open-label study is to perform a cost-effectiveness ratio (ICER), which is the ratio of the difference in cost between each strategy to the difference in their effects, as expressed in quality-adjusted life-years (QALYs) measured by the EuroQol Five-Dimension questionnaire (EQ-5D-5L) (https://euroqol.org/).

Secondary outcomes to be evaluated are as follows:
For both groups at 12 months: response and remission rate; relapse rate and survival without relapse; progression of the depressive state; cognitive performance; drug tolerability; suicide attempt rate and suicide rate; changes in instructions concerning medication and declared medication compliance.

For both groups at 5 years: budget impact analysis from the point of view of the National Health Insurance (NHI) to evaluate the financial impact of tDCS through different scenarios including the diffusion percentage of the technology and its reimbursement.

For group A only, at 12 months, response rate at end of tDCS treatments; annual number of tDCS sessions needed to maintain response; duration of tDCS response after initial treatment and after following ones: tDCS compliance, tolerability and security; patient’s acceptability of tDCS and how it is administered; identification
of response predictors and impact of tDCS implementation on healthcare organisation.

METHODS AND ANALYSIS

Study setting and recruitment

This is an ongoing, prospective, open-label, multicentre, randomised controlled study that shall recruit a total of 214 patients referred by either private or hospital psychiatrists previously informed about the study, randomly assigning half the patients to group A (experimental tDCS- TAU treatment) and half to group B (TAU-only treatment) for the purpose of comparison (figure 1). The study sponsor is Nantes CHU (Nantes University Hospital) in France. Patients will be included and treated at 12 centres in France. The study started in February 2019 and is planned to be completed in February 2022.

Inclusion criteria

All 214 patients must be over 18 years, present with a unipolar or bipolar depressive episode, as defined by the diagnostic criteria of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, score ≥15 on the Montgomery-Åsberg Depression Rating Scale (MADRS) and have failed to respond to one or two antidepressant drugs taken in succession or combination during the current episode. Each subject must be able to understand information given, make decisions, participate willingly, complete required questionnaires, take orally administered medication independently or with assistance throughout the study period and go to the study centre for follow-up visits. If patients agree to participate, they must give verbal consent to the medical investigator.

The current ‘pragmatic’ recruitment (ie, inclusion/exclusion criteria) is sufficiently broad to include a large representative sample of patient suffering from depression eligible to tDCS treatment.

Exclusion criteria

Patients may not be enrolled in the study if they have received electroconvulsive therapy or rTMS during the current episode; are suffering a major depressive episode with mixed or psychotic symptoms; are schizophrenic; are addicted to any substance except nicotine; are epileptic; have undergone neurosurgery or have a significant neurodegenerative disease; suffer from a severe or progressive somatic disease; have a pacemaker, an intracerebral implant containing metal, or another device or condition contraindicating tDCS administration; are pregnant and nursing women or women of childbearing age who are not using contraception; are enrolled in another interventional clinical trial; are minors or persons whose freedoms are restricted due to a legal or administrative decision or who are hospitalised without their consent, under guardianship or are unable to agree with longitudinal follow-up.

Study process

During the screening visit, patient information and verbal consent are obtained, patients are checked against inclusion and exclusion criteria and a psychiatrist performs a clinical evaluation (table 1). Medical research teams are in charge of enrolment and assignment of each participant to group A or B.

Inclusion visit and randomisation (day 0)

During the baseline inclusion visit, 1 week before the first tDCS session, patients are again checked against inclusion and exclusion criteria. They are then assigned to two groups through permuted block randomisation using a computer program and their electronic case report forms while stratifying by centre. No other variable is taking into account for the randomisation.

Follow-up

Investigators will meet study participants from both groups 1, 6 and 12 months after randomisation (M1, M6 and M12) (table 1). Group A patients will have an additional visit at M1, 4 weeks after the end of the initial 3-week round of tDCS sessions. Those group A participants who have responded to tDCS but whose condition is worsening at M1 will be offered an additional tDCS round, while those who have not responded will revert to the TAU for their respective study centres. In addition to follow-up visits, patients will receive phone calls at M6 and M12.

The study will last 36 months, including 24 months for enrolment and 12 for treatment and longitudinal follow-up. Patients who drop out of the study will be offered TAU. Drop-out dates and reasons will be recorded.
## Table 1 Calendar of study

<table>
<thead>
<tr>
<th>Study stage</th>
<th>D−7 (inclusion visit)</th>
<th>D0 (randomisation visit)</th>
<th>M1 (±7 days)</th>
<th>M2 (±15 days)</th>
<th>M3 (±15 days)</th>
<th>M6 (±15 days)</th>
<th>M9 (±15 days)</th>
<th>M12 (±15 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visits (C: centre; T: telephone call)</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C (group A)</td>
<td>T</td>
<td>C</td>
<td>T</td>
<td>C</td>
</tr>
<tr>
<td>Inclusion/exclusion criteria applied</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion and randomisation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease history, medical history and associated treatments</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scored using MADRS, Clinical Global Impression–Severity and Montreal Cognitive Assessment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>EuroQol Five-Dimension questionnaire</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Group A (tDCS-TAU): initial round of tDCS sessions (5 days/week for 3 weeks)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group A: additional rounds of tDCS in event of relapse (if patient responds well); total number of rounds is patient-dependent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tDCS acceptability</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compliance (MARS and Brief Medication Questionnaire)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Summary of depression treatments (pharmacological or other treatments)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Health economic data</td>
<td>X*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Microcosting with electronic case report form.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>†Medical resource consumption per NHSD.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dn, day; MADRS, Montgomery-Åsberg Depression Rating Scale; MARS, Medication Adherence Rating Scale; Mn, month; NHSD, National Health System Database; TAU, treatment as usual; tDCS, transcranial direct current stimulation.
Assessments

The following information will be recorded during the baseline visit ($D_0$): sociodemographic data (age, gender, laterality, professional status and marital status), medical history (duration of illness, duration of the current episode and psychiatric, addictive or somatic comorbidities), and current treatment.

Quality of life will be assessed with the EQ-5D-5L questionnaire at $D_0$, $M_1$, $M_2$, $M_2$; during group A $M_1$ follow-up consultations and at $M_1$ and $M_2$ by phone. MADRS, Beck Depression Inventory and Clinical Global Impression–Severity scores will be collected at $D_0$, $M_1$, $M_2$ (group A only), $M_3$ and $M_4$. Additional MADRS scores will be collected at the start and end of any additional round of tDCS sessions for group A patients who have relapsed. The Montreal Cognitive Assessment will be administered at $D_0$, $M_1$, $M_2$ and $M_4$. Acceptability and tolerability of tDCS will be assessed by visual analogue scale and Comfort Rating Questionnaires, respectively, following the initial round of tDCS sessions ($M_1$). Drug treatment compliance will be evaluated at $D_0$ and $M_4$ using the Medication Adherence Rating Scale, Compliance Rating Scale and Brief Medication Questionnaire. Compliance with the tDCS treatment plan will be evaluated by recording the actual number of tDCS sessions completed. At each visit, investigators will record any side effects and changes in treatment since the previous visit in the electronic case report form.

The cost-utility analysis will be performed with a societal perspective (ie, the broadest perspective), which means that costs to all stakeholders (NHI, hospitals, clinics, private insurances, patients) will be considered. Health services for all reasons will be included. Elements that may contribute to explain the differential in costs between the two groups are inpatient and outpatient health resources consumed, like outpatient psychiatric consultations, diagnosis-related groups, length of hospitalisations, pharmacotherapies, travel for medical care, medical imaging, laboratory analyses, nursing care, recourse to a psychologist or psychotherapist. Recourse to formal care (time spent by caregivers or home services) or informal care (time spent by relatives help), duration of work stoppage, loss of production capacity at the societal level and responses to Work Productivity and Activity Impairment questionnaires will also be collected. Data about the consumption of medical resources for which French NHI base prices exist will be extracted from the French National Health System Database (NHSD) (Système National des Données de Santé), which incorporates the French hospital expenditure database. Other resources consumed that are not covered by the NHI system will be collected via patient diaries fulfilled by the patient and reported into an electronic case report form. A microcosting approach will be used to evaluate the production cost of a tDCS session for the hospital; it will cover 15 ‘first sessions’ and the 15 ‘following sessions’ of tDCS in three centres participating in the study. The microcosting will consider time spent by staff, resources used including tDCS medical device.

When patients come in for follow-up visits, a survey on organisational impact (secondary end point) will be administered to each participating hospital team. The organisational impact will be assessed according to criteria extracted from the evaluation grid developed by Roussel et al."},13

We will carry out a 5-year budget impact analysis from the point of view of the NHI to evaluate the financial impact of tDCS through different scenarios, including the diffusion percentage of the technology and its reimbursement. To do this, we will assume a closed cohort over a year and use the 1 year management cost obtained in the cost-utility analysis.

Interventions

Two kinds of tDCS stimulator will be used in this study: the Soterix (Soterix Medical, New York, USA) and Sooma (Sooma Oy, Helsinki, Finland) devices, both of which bear CE product conformity marks. Units will be equally distributed between the 12 study centres. The montage allows for anodal stimulation of the left dorsolateral prefrontal cortex and cathodal stimulation of the right orbitofrontal cortex. On $D_1$, 1 week after randomisation, group A patients will commence an initial round of 30 min 2-mA tDCS treatment sessions every weekday for 3 weeks (15 sessions total). If they respond to tDCS but have relapsed, they will be offered an additional round of tDCS sessions following the $M_4$ assessment. If they are not responsive to tDCS, their respective centres are free to apply any therapeutic strategy.

TAU is defined as a wide range of standard and available treatments for major depressive and bipolar disorders, such as psychotherapy, medications and non-invasive brain stimulations.

Outcomes

The primary end point in our study is the ICER, comparing tDCS-TAU and TAU-only treatments for unipolar and bipolar depression, from a societal perspective, at $M_4$:

$$\text{ICER} = \frac{\text{Costs}_{\text{tDCS-}TAU\text{ arm}} - \text{Costs}_{\text{TAU} \text{ arm}}}{\text{QALYs}_{\text{tDCS-}TAU\text{ arm}} - \text{QALYs}_{\text{TAU} \text{ arm}}}$$

With $\text{Costs}_{\text{tDCS-}TAU\text{ arm}}$ and $\text{Costs}_{\text{TAU} \text{ arm}}$: mean direct costs per patient in each arm.

With $\text{QALYs}_{\text{tDCS-}TAU\text{ arm}}$ and $\text{QALYs}_{\text{TAU} \text{ arm}}$: mean QALYs per patient in each arm.

QALYs will be determined using EQ-5D-5L questionnaires administered at seven time points. QALYs will be calculated using area under the curve methodology and the weighting coefficients that will be provided soon in France for the EQ-5D-5L. If they are not available at the time of analysis, a mapping between EQ-5D-3L and EQ-5D-5L will be achieved in order to get relevant weights. The cost-utility analysis will be performed in accordance with French Health Authority (HAS) recommendations.

Direct costs will be included in the primary analysis taking into account all stakeholders (NHI, hospitals, private insurance companies, patients and caregivers) to acquire the desired societal perspective. In a secondary
analysis, direct and indirect costs will be included. While
direct costs relate to the resources needed for the produc-
tion of the interventions being studied, other resources
may be made unavailable because of the mortality and/
or morbidity. These lost resources, as productivity loss,
are included as indirect costs. The 12-month period
following randomisation affords time to estimate the
impact of tDCS on patient quality of life and costs during
depressive episodes, detect relapses or recurrences and
identify potential medication complications. No cost or
QALY discount will be applied given the duration of this
period.

Cost estimation will follow three steps: (1) identification
and quantification of resources consumed, (2) determina-
tion of unit costs for resources and (3) multiplication
of resource quantities by corresponding unit costs to
estimate total costs. Resources used will be determined
using the French NHSD and recorded on participants’
electronic case report forms. Direct costs will be deter-
dined by applying NHI base prices. Costs of psychologist
appointments and home services—as these are assigned
no NHI base prices—will be determined using the
national mean fee and national mean cost, respectively.
Indirect costs, as reflected by loss of production during
work stoppage and responses to Work Productivity and
Activity Impairment questionnaires, will be evaluated by
applying a national mean wage to work stoppage dura-
tions (human capital approach). Informal care will be
valued by applying the national mean cost for domestic
helpers to the time spent by caregivers.

**Statistical methods**

**Sample size calculation**

To our knowledge, no published study has evaluated the
quality of life, healthcare resource consumption and costs
associated with tDCS treatment for depression, meaning
there is no precedent for establishing the number of
subjects needed for our study with the formula by Glick.46
We therefore determined this number using a clinical
efficacy criterion.

We hypothesised tDCS-TAU response rate of 60% at
M114 47 and a TAU-only response rate of 40%. Assuming
a 5% (two-tailed) type I error, a power of 80% and an
attrition rate of 10%, a total of 214 subjects are required
(107 subjects per arm) according to SAS software V.9.4.

**Principal end point: cost-utility analysis**

The principle of ‘intention to treat’ will be applied when
performing the cost-utility analysis. Where necessary,
missing data will be imputed. Data extracted from
the French NHSD are considered as complete and do not
necessitate imputation, but missing data from QALYs
and costs (only for the non-reimbursed health resources)
will be imputed with multiple imputations by chained
equations (MICE), according to the method proposed
by Faria et al.48 Analyses with and without imputed data
will be presented. The primary analysis will be the analysis
with imputed data.

Costs per patient will be presented in each arm in a
table, disaggregated in cost items (eg, hospitalisations,
medical visits, drugs, etc) with their mean and 95% CI.
The total mean costs, total mean QALYs, mean life years
gained per patient in each arm and the differences in
costs and in QALYS between groups will be presented
in another table with their mean and 95% CI. The
ICER will be presented in this latter table. The 95% CIs
will be calculated (two possible approaches to do so; by
non-parametric bootstrapping49 or seemingly unrelated
regression (SUR)). If the baseline quality of life differs
between groups A and B, adjustment will be performed
(two possible approaches to do so: either in the SUR,
or in the regression that is performed before bootstrap-
ing). Results will be tabulated.

For the decision criteria of cost-effectiveness, we arbit-
arily chose a value of €50 000/QALY because a threshold
value for a QALY has yet to be recommended in France.
This value seems to be acceptable in France. Results will
also be presented using an acceptability curve showing
the probability that tDCS-TAU is cost-effective compared
with TAU-only treatment using several values of societal
willingness to pay for a QALY. A sensitivity analysis will be
performed to assess the robustness of the results, through
variation of some relevant parameters (eg, national mean
fees, national mean costs, respectively for psychologist
visits or home services).

**Clinical end points: quality of data collected, population analysed
and statistical methods**

Data will be reviewed at the end of the study, prior to
statistical analysis. The aim will be to identify the progress
made and potential problems, and to classify any minor
or major deviations.

The primary analysis population will be the ‘intention-
to-treat population’, consisting of all the randomised
patients. In addition, a sensitivity analysis will be conducted
on the ‘per-protocol’ population, which includes patients
who most closely adhere to the protocol (compliance
with inclusion and non-inclusion criteria, lack of major
protocol deviations and availability of primary end point
data).

Descriptive analysis of the data collected during each
patient’s evaluation will be performed up until the
final evaluation. Both subject groups will be analysed
at D0 (baseline) and M12. Continuous variables will be
described using quartiles, means, SD and extreme values,
while frequencies and percentages will be used for qual-
itative variables.

Remission, response and relapse rates (and their corre-
sponding 95% CIs) at M12 for groups A and B will be
compared using the generalised linear model (logistic
model) and considering study centre to be a random
factor (randomisation stratification factor). Relapse-
free survival rates until M12 will be estimated using the
Kaplan-Meier method and compared between two groups
through the log-rank test using stratification by study
centre. Sustainability (or maintenance) of the therapeutic
response over time will be assessed through Cox multivariate analysis.

Changes in MADRS, Clinical Global Impression–Severity and Montreal Cognitive Assessment scores for both groups between D₀ and M₁₂ will be compared using linear mixed regression models and making study centre a random factor. The model will be adjusted according to D₀ scores. M₀ scores, only available for group A participants, will not be included.

Pharmacological treatment modifications and side effects will be described and compared by participant group using a χ² test (or Fisher’s exact test, if appropriate). The numbers and percentages of suicidal attempts for each group will be compared using Fisher’s exact test.

Medication Adherence Rating Scale, Compliance Rating Scale and Brief Medication Questionnaire scores for each group at M₁₂ will be compared using linear mixed regression models and making study centre a random factor. Non-compliance percentages will also be determined for both groups.

For all outcomes, mean differences between the two groups, and the corresponding 95% CIs, will be reported. The following criteria will be described at D₀ and M₁₂ for group A patients: tDCS response rate; number of tDCS rounds prescribed; efficacy and side effects of each tDCS round; compliance rate and the acceptability of the procedure, measured using the visual analogue scale. Missing data will be described for both groups. If required, imputation will be performed for missing data on clinical response, remission and relapse. First, it will be assumed that the patients concerned exhibited no response, remission or relapse. Second, sensitivity analyses will be performed using MICE on the basis of main patient characteristics. For clinical criteria other than response, remission and relapse, there will be no imputation. Secondary clinical outcomes (MADRS, Clinical Global Impression–Severity and Montreal Cognitive Assessment scores) will not be imputed because they are analysed using a repeated measures mixed model that is robust to missing data.

Analyses will be performed with SAS statistical software (SAS Institute). Statistical tests will be two-sided, and p values <0.05 shall be deemed statistically significant.

**Patient and public involvement**

There was neither patient nor public involvement in the development of this study protocol.

**ETHICS AND DISSEMINATION**

**Consent**

Information about the study’s aim and procedures is provided to all volunteer participants both verbally and in writing. Patients must provide oral consent to participate in the study. They are informed that participation is voluntary and that they may withdraw their consent at any time.

**Dissemination policy**

Data from the study will be published in a peer-reviewed medical journal.

**DISCUSSION**

The current challenges faced in the treatment of depressive disorders are to reduce relapses, recurrences and chronicity, and to optimise the consumption of healthcare resources for the management of depression. To meet these challenges, the prevention of pharmacological resistance and the promotion of adherence through better treatment tolerability, acceptability, feasibility and accessibility to patients as a first resort are paramount. Non-invasive brain stimulation, through techniques such as rTMS and tDCS, are recognised as effective therapeutic alternatives for the treatment of depressive disorders, boasting high levels of adherence and tolerability in comparison with pharmacological treatments. The tRMS procedure has proved more effective than antidepressants after a first treatment failure for MDD in newly diagnosed patients or at least two well-conducted antidepressant treatments. To date, no cost-effectiveness study has been conducted for tDCS in depression, although there have been cost-effectiveness studies that compared rTMS with medication and with electroconvulsive therapy. The tDCS procedure has the advantage of being easier to perform and less expensive than rTMS. In two previous studies assessing the production costs of rTMS and tDCS (respectively) for the treatment of depression, we found tDCS to be less expensive. The DISCO study protocol is the first economic evaluation to use cost-utility analysis for the comparison of tDCS-TAU and TAU-only treatments in patients with depression. The French government has yet to determine a base price for TAU and TAU-only treatments by calculating volumes of resources consumed, determining the unit costs of these resources and multiplying the calculated volumes by the unit costs. To evaluate the overall cost of depression, estimation of direct medical and technical costs will not suffice because the indirect costs are not trivial and cannot be ignored. Thus, DISCO will address direct costs through its primary analysis and indirect costs through a secondary analysis, in accordance with HAS recommendations. To estimate indirect costs, the study will consider loss of production due to work stoppage—applying the human capital approach—and responses to Work Productivity and Activity Impairment questionnaires data on the involvement of caregivers will also be collected through electronic case report form questionnaires, to measure the informal costs of depression.
From a clinical perspective, DISCO will offer new insights concerning primary care of patients with non-treatment-resistant unipolar or bipolar depression. It also boasts one of the longest follow-ups among brain stimulation studies.

As any cost-effectiveness study protocols, DISCO strives to reflect clinical realities. The long-term effects of tDCS in depression are still poorly understood. In one study, 3 months after a 10-session tDCS treatment programme, 45% of the patients were still in remission. It appears that depression relapse rates are higher when protocols call for entailing weekly session at a bi-monthly rate, and when treatment resistance are higher at baseline.

More recent publications therefore recommend studies with longer follow-ups and maintenance tDCS. One of the secondary aims of DISCO is to determine the number of tDCS sessions needed to maintain remission in patients with depressive disorder responding to an initial round of tDCS sessions in combination with TAU. Further tDCS sessions will only be offered if patients respond to tDCS and then relapse. This flexible design, tailored to participants’ unique needs, more closely models real clinical practice than a rigid timepoint protocol, and it benefits both patients and study centres.

As a real-life study, DISCO does not call for changes in current treatments. Furthermore, adjuvant tDCS has shown the potential to synergistically increase the efficacy of both pharmacological (including antidepressant) and non-pharmacological treatments.

In conclusion, we assume that the addition of tDCS will offer greater efficacy than the usual treatments alone—as reflected by quality of life, number of hospitalisations, drug consumption, and societal repercussions. If our main hypothesis is confirmed, this study will provide evidence in support of tDCS as an add-on treatment for patients with non-treatment-resistant depression, and it will demonstrate—for the first time ever—that it is an efficient and effective therapeutic strategy. This would in turn offer justification for government reimbursement of tDCS procedures in France—and perhaps in other countries.

Trial status
Patient recruitment is in progress.

Author affiliations
1CHU de Nantes, Addictology and Liaison Psychiatry Department, Hospital University of Nantes, Nantes, France
2Nantes Université, CHU Nantes, Movement, Interactions, Performance (MIP), EA 4324, University of Nantes, Nantes, France
3CHU de Nantes, Innovation Cell, Partnership and Innovation Department, Directorate of Medical Affairs and Research, University Hospital Centre Nantes, Nantes, France
4CHU de Nantes, Section of Methodology and Biostatistics, University Hospital Centre Nantes, Nantes, Pays de la Loire, France
5Réseau HUGOPSy, Université de Rennes, Rennes, France
6Department of Neurosciences, Reproductive Sciences, and Odontostomatoloy, University of Naples Federico II, Napoli, Campania, Italy
7Inserm, SPhIERE U1246, University of Nantes, Nantes, Pays de la Loire, France

Twitter Fabienne Tessler @FabienneTESSIER

Acknowledgements The authors would like to thank Mr Jason Miller for the editing of the manuscript.

Collaborators DISCO investigators group: Bénédicte Gohier (Department of Psychiatry and Addictology, Angers University Hospital, University, UPRES EA 4638, University of Angers, 49100 Angers), Marine Rozet (Department of Psychiatry and Addictology, Angers University Hospital, University, UPRES EA 4638, University of Angers, 49100 Angers). Djamilia Bennabi (Service de Psychiatrie, CIC-1431 INSERM, CHU de Besançon, F-25000 Besançon, France : laboratoire de Neurosciences, Université Bourgogne Franche-Comté, F-25000 Besançon, France), Emmanuel Hafften (Service de Psychiatrie, CIC-1431 INSERM, CHU de Besançon, F-25000 Besançon, France ; laboratoire de Neurosciences, Université Bourgogne Franche-Comté, F-25000 Besançon, France), Christophe Daudet (Clinique Mirambeau 22 Avenue De Maignon, 64600 Anglet, France), Ludovic Samalin (CHU Clermont-Ferrand, Department of Psychiatry, University of Clermont Auvergne, EA 7280, Clermont-Ferrand, France; Fondation Fondamental, Créteil, France), Pierre-Michel Llorca (CHU Clermont-Ferrand, Department of Psychiatry, University of Clermont Auvergne, EA 7280, Clermont-Ferrand, France; Fondation Fondamental, Créteil, France), Benoît Trojan (University Hospital of Dijon, Department of Psychiatry and Addictology, 21079 Dijon, France), Jean-Christophe Chauvet-Gélinier (Psychiatry unit, department of neurosciences, university hospital, CHU de Le Bocage, Bâtiment Marion, 14, rue Gaffarel, 21000 Dijon, France; Inserm LNC-UMR 1231, 21000 Dijon, France), Emmanuel Poulet (INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Psychiatric Disorders: from Resistance to Response Team, Lyon, F-69000, France; University Lyon 1, Villeurbanne, F-69000, France; Department of Emergency Psychiatry, University Hospital Edouard Herriot, Hospices civils de Lyon, Lyon, France), Charline Magnin (INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Psychiatric Disorders: from Resistance to Response Team, Lyon, F-69000, France; University Lyon 1, Villeurbanne, F-69000, France; Department of Emergency Psychiatry, University Hospital Edouard Herriot, Hospices civils de Lyon, Lyon, France), Stéphane Mouchabac (Sorbonne Universités, département de psychiatrie adulte et de psychologie médicale, AP-HP, hôpital Saint-Antoine, Paris, France), Ghina Harika Germeau (Université de Poitiers, Unité de recherche clinique intersectorielle en psychiatrie à vocation régionale Pierre Deniker du Centre Hospitalier Henri Laborit F-86022 France : Groupe de Recherche CNRS 3557), Nemat Jaafar (Université de Poitiers, Unité de recherche clinique intersectorielle en psychiatrie à vocation régionale Pierre Deniker du Centre Hospitalier Henri Laborit F-86022 France; Groupe de Recherche CNRS 3557), Dominique Drapier (Centre Hospitalier Guillaume Régnier, 108 avenue général leclerc 35 703 Rennes ; EA 4712 Comportements et noyaux gris centraux, Université Rennes I, France), Jean-Marie Batail (Centre Hospitalier Guillaume Régnier, 108 avenue général leclerc 35 703 Rennes ; EA 4712 Comportements et noyaux gris centraux, Université Rennes 1, France), Maud Rothamel (Service Hospitalo-Universitaire, Centre Hospitalier du Rouvray, 4, rue Paul Eluard, 76300 Sotteville-lès-Rouen, France), Caroline Benjamin (Service Hospitalo-Universitaire, Centre Hospitalier du Rouvray, 4, rue Paul Eluard, 76300 Sotteville-lès-Rouen, France), El-Hage Wasseem (CHRU de Tours, Pôle de Psychiatrie, Tours, France), UMR 1253, iBrain, Université de Tours, Inserm, Tours, France ; CC 1415, Centre d’Investigation Clinique, Inserm, CHRU de Tours, Tours, France), Desmidt Thomas (CHRU de Tours, Pôle de Psychiatrie, Tours, France ; UMR 1253, iBrain, Université de Tours, Inserm, Tours, France).

Contributors AS, CV, SS-B, MP, AT, SB, J-MV, V-PR and MG designed the study and developed its protocol. AS is the study coordinator. AS, LL, GD’U, V-PR and SCB wrote the first version of the manuscript. AS, BB, NC, MG, AB, LS, the HUGOPSy network, the DISCO investigators group are investigators and responsible for enrolment, determining treatment indications and data collection. All the authors (AS, LL, SS-B, CV, MP, CD, AR, FT, AT, TD, VT-O, AR, NP, CC, NB, MG, AB, LS, BG, MR, OB, EH, CD, LS, P-ML, BT, J-CC-G, EP, CM, SM, NJ, GHG, DD, J-MB, MR, CB, E-HW, TD, J-MV, GD’U, V-PR) are involved in the data acquisition. CD is the project manager, helped with general organisation and sought ethical and regulatory approval. FT and AR are project managers assistants. FT, AR, AP, AL, AR and LL contributed to DISC administration and treatment planning. V-PR, MP and CV are responsible for calculating statistical power and performing statistical analyses. FT, LL, TD, VT-O, NP and AB are in charge of planning, randomisation and completion of electronic case report forms. All the authors read the draft critically, and approved the final version. All the authors agreed to be accountable for all aspects of the work.

Funding This work was supported by the French Ministry of Health (project PRME-17-0097).

Competing interests None declared.
Patient consent for publication Not required.

Ethics approval This study has been approved by a French ethics committee, the CPP- Est IV (Comité de Protection des Personnes–Strasbourg) (RCB no. 2015-A00474-51; ERB no. 18/75) and designed in accordance with the Declaration of Helsinki (final 2004 version) and French legislation (articles L1121-160 and L1126-7 of the French public health code).

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Anne Sauvaget http://orcid.org/0000-0002-1822-8535

REFERENCES


